The interaction of Urocortin II and Urocortin III with amygdalar and hypothalamic cotricotropin-releasing factor (CRF) - Reflections on the regulation of the hypothalamic-pituitary-adrenal (HPA) axis

Zsolt Bagosi, Krisztina Csabafi, Miklós Palotai, M. Jászberényi, I. Földesi, J. Gardi, Gyula Szabó, G. Telegdy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Urocortin II (Ucn II) and Urocortin III (Ucn III) are selective agonists of the CRF receptor type 2 (CRFR2). The aim of the present experiments was to investigate the effects of Ucn II and Ucn III on the central CRF and peripheral glucocorticoids in rats. Increasing doses (0.5-1-2-5. μg/2. μl) of Ucn II or Ucn III were administered intracerebroventricularly, then CRF concentration was determined by immunoassays in two different brain regions, the amygdala and the hypothalamus, and in two different time paradigms, 5 and 30. min after the administration of peptides. In parallel with the second determination, plasma corticosterone concentration was measured by chemofluorescent assay. The amygdalar CRF amount was increased significantly by 0.5 and 5. μg of UCN II and 2 and 5. μg of UCN III in the 5. min experiments and by 5. μg of UCN II and 0.5 and 5. μg of UCN III in the 30. min experiments. The hypothalamic CRF content was not affected considerably in the 5. min paradigm, but it was influenced significantly in the 30. min paradigm, with 0.5 and 1. μg of UCN II and 0.5-2. μg of UCN III decreasing, and 2 and 5. μg of UCN II and 5. μg of UCN III increasing the hormone concentration, respectively. The plasma corticosterone concentration was decreased by 1 and 2. μg of UCN II and UCN III and increased by 0.5 and 5. μg of UCN III. The present results demonstrate that central administration of Ucn II and Ucn III modulate time-dependently and dose-dependently the amygdalar and the hypothalamic CRF concentration, and, directly or indirectly, the plasma corticosterone concentration. The present experiments suggest that the role of CRFR2 in the regulation of the HPA axis can be inhibitory or stimulatory, depending on the actual concentration of their agonists.

Original languageEnglish
Pages (from-to)333-338
Number of pages6
JournalNeuropeptides
Volume47
Issue number5
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Urocortins
Pituitary Hormone-Releasing Hormones
Corticosterone

Keywords

  • Corticosterone
  • CRF
  • HPA axis
  • Urocortin II
  • Urocortin III

ASJC Scopus subject areas

  • Endocrinology
  • Neurology
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems

Cite this

@article{2c05527529244976ac0e9fda10fe54e5,
title = "The interaction of Urocortin II and Urocortin III with amygdalar and hypothalamic cotricotropin-releasing factor (CRF) - Reflections on the regulation of the hypothalamic-pituitary-adrenal (HPA) axis",
abstract = "Urocortin II (Ucn II) and Urocortin III (Ucn III) are selective agonists of the CRF receptor type 2 (CRFR2). The aim of the present experiments was to investigate the effects of Ucn II and Ucn III on the central CRF and peripheral glucocorticoids in rats. Increasing doses (0.5-1-2-5. μg/2. μl) of Ucn II or Ucn III were administered intracerebroventricularly, then CRF concentration was determined by immunoassays in two different brain regions, the amygdala and the hypothalamus, and in two different time paradigms, 5 and 30. min after the administration of peptides. In parallel with the second determination, plasma corticosterone concentration was measured by chemofluorescent assay. The amygdalar CRF amount was increased significantly by 0.5 and 5. μg of UCN II and 2 and 5. μg of UCN III in the 5. min experiments and by 5. μg of UCN II and 0.5 and 5. μg of UCN III in the 30. min experiments. The hypothalamic CRF content was not affected considerably in the 5. min paradigm, but it was influenced significantly in the 30. min paradigm, with 0.5 and 1. μg of UCN II and 0.5-2. μg of UCN III decreasing, and 2 and 5. μg of UCN II and 5. μg of UCN III increasing the hormone concentration, respectively. The plasma corticosterone concentration was decreased by 1 and 2. μg of UCN II and UCN III and increased by 0.5 and 5. μg of UCN III. The present results demonstrate that central administration of Ucn II and Ucn III modulate time-dependently and dose-dependently the amygdalar and the hypothalamic CRF concentration, and, directly or indirectly, the plasma corticosterone concentration. The present experiments suggest that the role of CRFR2 in the regulation of the HPA axis can be inhibitory or stimulatory, depending on the actual concentration of their agonists.",
keywords = "Corticosterone, CRF, HPA axis, Urocortin II, Urocortin III",
author = "Zsolt Bagosi and Krisztina Csabafi and Mikl{\'o}s Palotai and M. J{\'a}szber{\'e}nyi and I. F{\"o}ldesi and J. Gardi and Gyula Szab{\'o} and G. Telegdy",
year = "2013",
month = "10",
doi = "10.1016/j.npep.2013.07.001",
language = "English",
volume = "47",
pages = "333--338",
journal = "Neuropeptides",
issn = "0143-4179",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - The interaction of Urocortin II and Urocortin III with amygdalar and hypothalamic cotricotropin-releasing factor (CRF) - Reflections on the regulation of the hypothalamic-pituitary-adrenal (HPA) axis

AU - Bagosi, Zsolt

AU - Csabafi, Krisztina

AU - Palotai, Miklós

AU - Jászberényi, M.

AU - Földesi, I.

AU - Gardi, J.

AU - Szabó, Gyula

AU - Telegdy, G.

PY - 2013/10

Y1 - 2013/10

N2 - Urocortin II (Ucn II) and Urocortin III (Ucn III) are selective agonists of the CRF receptor type 2 (CRFR2). The aim of the present experiments was to investigate the effects of Ucn II and Ucn III on the central CRF and peripheral glucocorticoids in rats. Increasing doses (0.5-1-2-5. μg/2. μl) of Ucn II or Ucn III were administered intracerebroventricularly, then CRF concentration was determined by immunoassays in two different brain regions, the amygdala and the hypothalamus, and in two different time paradigms, 5 and 30. min after the administration of peptides. In parallel with the second determination, plasma corticosterone concentration was measured by chemofluorescent assay. The amygdalar CRF amount was increased significantly by 0.5 and 5. μg of UCN II and 2 and 5. μg of UCN III in the 5. min experiments and by 5. μg of UCN II and 0.5 and 5. μg of UCN III in the 30. min experiments. The hypothalamic CRF content was not affected considerably in the 5. min paradigm, but it was influenced significantly in the 30. min paradigm, with 0.5 and 1. μg of UCN II and 0.5-2. μg of UCN III decreasing, and 2 and 5. μg of UCN II and 5. μg of UCN III increasing the hormone concentration, respectively. The plasma corticosterone concentration was decreased by 1 and 2. μg of UCN II and UCN III and increased by 0.5 and 5. μg of UCN III. The present results demonstrate that central administration of Ucn II and Ucn III modulate time-dependently and dose-dependently the amygdalar and the hypothalamic CRF concentration, and, directly or indirectly, the plasma corticosterone concentration. The present experiments suggest that the role of CRFR2 in the regulation of the HPA axis can be inhibitory or stimulatory, depending on the actual concentration of their agonists.

AB - Urocortin II (Ucn II) and Urocortin III (Ucn III) are selective agonists of the CRF receptor type 2 (CRFR2). The aim of the present experiments was to investigate the effects of Ucn II and Ucn III on the central CRF and peripheral glucocorticoids in rats. Increasing doses (0.5-1-2-5. μg/2. μl) of Ucn II or Ucn III were administered intracerebroventricularly, then CRF concentration was determined by immunoassays in two different brain regions, the amygdala and the hypothalamus, and in two different time paradigms, 5 and 30. min after the administration of peptides. In parallel with the second determination, plasma corticosterone concentration was measured by chemofluorescent assay. The amygdalar CRF amount was increased significantly by 0.5 and 5. μg of UCN II and 2 and 5. μg of UCN III in the 5. min experiments and by 5. μg of UCN II and 0.5 and 5. μg of UCN III in the 30. min experiments. The hypothalamic CRF content was not affected considerably in the 5. min paradigm, but it was influenced significantly in the 30. min paradigm, with 0.5 and 1. μg of UCN II and 0.5-2. μg of UCN III decreasing, and 2 and 5. μg of UCN II and 5. μg of UCN III increasing the hormone concentration, respectively. The plasma corticosterone concentration was decreased by 1 and 2. μg of UCN II and UCN III and increased by 0.5 and 5. μg of UCN III. The present results demonstrate that central administration of Ucn II and Ucn III modulate time-dependently and dose-dependently the amygdalar and the hypothalamic CRF concentration, and, directly or indirectly, the plasma corticosterone concentration. The present experiments suggest that the role of CRFR2 in the regulation of the HPA axis can be inhibitory or stimulatory, depending on the actual concentration of their agonists.

KW - Corticosterone

KW - CRF

KW - HPA axis

KW - Urocortin II

KW - Urocortin III

UR - http://www.scopus.com/inward/record.url?scp=84886946137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886946137&partnerID=8YFLogxK

U2 - 10.1016/j.npep.2013.07.001

DO - 10.1016/j.npep.2013.07.001

M3 - Article

C2 - 23932308

AN - SCOPUS:84886946137

VL - 47

SP - 333

EP - 338

JO - Neuropeptides

JF - Neuropeptides

SN - 0143-4179

IS - 5

ER -